Raphael Pharmaceutical (RAPH) Change in Accured Expenses (2025)
Raphael Pharmaceutical's (RAPH) quarterly Change in Accured Expenses came in at $31000.0 in Q4 2025, up 1450.0% quarter-over-quarter from $2000.0 in Q3 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Change in Accured Expenses (2025) Analysis & Trends
Raphael Pharmaceutical has disclosed Change in Accured Expenses across 1 years of filings, most recently posting $31000.0 for Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |